Supreme Court rules generic Vascepa copy does not infringe patents, boosting skinny-label pathway

The U.S. Supreme Court issued a decision that Hikma Pharmaceuticals’ generic version of Amarin’s heart drug Vascepa does not infringe the brand’s patents. The ruling clarified that the generic maker did not induce use of the drug for an unapproved indication, a key factor in the judgment.

The case centered on the practice of “skinny labeling,” where a generic seeks FDA approval for a limited indication that is no longer protected by exclusivity. This allows the generic to enter the market earlier than waiting for the full patent term to expire.

The decision is seen as a win for generic manufacturers, potentially easing legal challenges tied to skinny‑label strategies and expanding access to lower‑cost medicines. It also signals to brand‑name companies that patent enforcement may be limited when generics operate within narrow, approved uses.